Sevikar HCT combines olmesartan medoxomil, amlodipine and hydrochlorothiazide (HCT) in a single pill to help improve patient compliance and manage hypertension more effectively.
It is indicated for patients who are already taking these three drugs in the form of Olmesartan Plus and amlodipine, and is available in five different fixed doses to meet varied patient needs.
Research has shown that up to 80% of the 2 million UK patients who are prescribed three or more anti-hypertensive drugs are not compliant with their treatment, putting many of them at risk of stroke or heart disease.
Strokes resulting from hypertension cost the NHS an estimated £2.8 billion per year, and are a major cause of disability.
Clinical studies have shown that replacing multiple prescriptions with a single-pill combination can improve compliance rates and hence improve blood pressure control.
“A simplified treatment regimen for those patients taking three or more tablets makes eminent sense for hypertension and could lead to improved compliance rates”, said Professor Tony Heagerty, Head of the Cardiovascular Research Group at Manchester University.
“After lifestyle advice, medication is the most powerful way of managing high blood pressure, but only when it is taken correctly.”
The Daiichi Sankyo Group aims to develop pharmaceutical products to target diversified and unmet patient needs.